Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application

Bulletin Express

02/13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.

As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1116626955"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116626955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116626955?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116626955","market":"us","top_or_hot":-1,"title":"Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.</p>\n<p>As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-02-13 18:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.</p>\n<p>As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"復星醫藥","start_time":0,"source_url":"","article_id":"1116626955","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116626955","pubTimestamp":1770976897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196)公告子公司顺铂注射液注册申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.\nAs of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}